Moore Capital Management’s Haemonetics HAE Stock Holding History

Moore Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-50,000	Closed	-$2.9M	–	266
2017 Q4	$2.9M	Buy	+50,000	New	+$2.63M	0.05%	173

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Moore Capital Management's HAE Position: Q1 2018 in Review

Moore Capital Management sold out of Haemonetics (HAE) in Q1 2018, closing a stake of 50,000 shares — an estimated $2.9M sold.

Moore Capital Management first reported a position in HAE in Q4 2017 and held it in 1 quarter. The position peaked at $2.9M in Q4 2017. 261 funds tracked by Wall St. Rank hold HAE as of Q1 2018.

Moore Capital Management reported no remaining Haemonetics position as of Q1 2018 after selling out during the quarter.
Moore Capital Management sold 50,000 Haemonetics shares in Q1 2018, an estimated $2.9M.
Moore Capital Management first reported a position in Haemonetics in Q4 2017 and held it in 1 quarter.
Moore Capital Management's Haemonetics position peaked at $2.9M in Q4 2017.
261 funds tracked by Wall St. Rank held Haemonetics as of Q1 2018.

Based on Moore Capital Management's 13F filing for Q1 2018, filed 15 May 2018.